Luisa M. Solis

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

Carl M. Gay, C. Allison Stewart, Elizabeth M. Park et al. · Cancer Cell · 2021 · 932 citations · Full text

Medicine, Cancer Biology, Molecular Biology +10

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone, William N. William, Annikka Weissferdt et al. · Nature Medicine · 2021 · 604 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Mechanical regulation of glycolysis via cytoskeleton architecture

Jin Suk Park, Christoph J. Burckhardt, Rossana Lazcano et al. · Nature · 2020 · 596 citations · Full text

Life Sciences, Biochemistry, Cell Biology +14

Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features

Luisa M. Solis, Carmen Behrens, Wenli Dong et al. · Clinical Cancer Research · 2010 · 424 citations · Full text

Medicine, Molecular Biology, Oncology +17

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Tina Cascone, Cheuk Hong Leung, Annikka Weissferdt et al. · Nature Medicine · 2023 · 206 citations · Full text

Medicine, Oncology, Pharmacology +17